Comparing oncological outcomes and safety between photodynamic diagnosis-assisted and white-light transurethral resection in elderly patients with non-muscle invasive bladder cancer
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf047 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Yuto Matsushita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka 431-3192, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study aimed to assess the prognostic outcomes and risk of adverse events in elderly non-muscle invasive bladder cancer (NMIBC) patients receiving photodynamic diagnosis-assisted transurethral resection of bladder cancer (PDD-TURBT).
Methods
This study retrospectively included 326 patients who were over 70 years old and received either PDD-TURBT (n = 114, PDD group) or white-light TURBT (n = 212, WL group). Oncological outcomes, namely recurrence-free survival (RFS) and progression-free survival (PFS), and adverse event profiles were compared between the two groups.
Results
In the PDD and WL groups, the median RFS periods were not reached and 41.7 months (P < 0.001), and the median PFS periods were not reached and 160.2 months (P = 0.057), respectively. The Grey test which take account to overall death as a competing risk event revealed recurrence tended to decrease in PDD group (P = 0.050). The independent prognostic factors were determined by multivariate Cox regression analyses: WL-TURBT in RFS. After propensity score matching, statistically favorable RFS in the PDD group were shown (P = 0.018). The incidence of AST/ALT elevation and intraoperative hypotension (defined as systolic blood pressure ≤ 80 mmHg) were significantly higher in the PDD group than in the WL group (P = 0.003 and 0.003, respectively).
Conclusions
Prolonged RFS are expected for PDD-TURBT using oral 5-aminolevulinic acid in elderly NMIBC patients. However, the risks of liver injury and intraoperative hypotension are higher for PDD-TURBT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka 431-3192, Japan.
- Department of Developed Studies for Advanced Robotic Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka 431-3192, Japan.
ORCID-Profile: Yuto Matsushita, Kyohei Watanabe
Zitieren
APA
Matsushita, Y., Tsuchiya, Y., Ishikawa, G., Sano, A., Takemura, A., Watanabe, S., Watanabe, K., Watanabe, H., Tamura, K., Motoyama, D., Otsuka, A., & Inamoto, T. (2025). Comparing oncological outcomes and safety between photodynamic diagnosis-assisted and white-light transurethral resection in elderly patients with non-muscle invasive bladder cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf047
Vancouver
Matsushita Y, Tsuchiya Y, Ishikawa G, Sano A, Takemura A, Watanabe S, et al. Comparing oncological outcomes and safety between photodynamic diagnosis-assisted and white-light transurethral resection in elderly patients with non-muscle invasive bladder cancer. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf047
BibTeX
@article{Matsushita2025,
author = {Matsushita, Yuto and Tsuchiya, Yoshihiro and Ishikawa, Gaku and Sano, Asuka and Takemura, Ayana and Watanabe, Shunsuke and Watanabe, Kyohei and Watanabe, Hiromitsu and Tamura, Keita and Motoyama, Daisuke and Otsuka, Atsushi and Inamoto, Teruo},
title = {Comparing oncological outcomes and safety between photodynamic diagnosis-assisted and white-light transurethral resection in elderly patients with non-muscle invasive bladder cancer},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf047}
}
EUVIMED